Abstract: Compounds of a general structural formula (I) and salts and solvates thereof, and use of the compounds as PDES inhibitor.

Abstract: Preparation of alkylthio and/or arylthio-substituted diketo-diaryl-pyrrolopyrroles (DPPs) of the formula Ia and dithio-bridged bis-diketo-diaryl-pyrrolopyrroles (bis-DPPs) of the formula Ib in which in formula Ia G is phenyl substituted by at least one arylthio or alkylthio group, and G1 is G or a carbocyclic or heterocyclic radical, by reacting a haloaryl with a thiol or thiolate, and in formula Ib G5 is a phenylene, G6 is G1 but not G, and G7 is alkylene, cycloalkylene or phenylene, by reacting two haloaryls with a dithiol or dithiolate, which comprises reacting a thiol or thiolate with a halo-diketo-diaryl-pyrrolopyrrole (“halo-DPP”) of the formula IIa in which G2 is a halogenated phenyl group and G3 is G2 or G1, or reacting a dithiol or dithiolate with two halo-diketo-diaryl-pyrrolopyrroles (“halo-DPPs”) of the formula IIb in which Hal is halogen such as fluorine, chlorine, bromine or iodine, and G6 is G1, and also novel DPPs a

Abstract: The invention relates to therapeutic benzamide compounds of formula (I) wherein A, X, Z, R1, Y, R2, R3, are as defined herein, and physiologically acceptable salts, solvates or derivatives thereof. The present invention also provides pharmaceutical compositions, processes for the preparation of compounds of formula (I) and their use in the treatment of conditions mediated by ApoB-100 regulation.

Abstract: A compound of formula (I) 1

Abstract: A compound of formula (I) and salts and solvates thereof, in which: R0 represents hydrogen, halogen or C1-6 alkyl; R1 represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring  attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain.

Abstract: A compound of formula and salts and solvates thereof, wherein R0, R1, and R2 are defined in the specification. A compound of the present invention is a potent and selective inhibitor of cGMP-specific PDE and has utility in a variety of therapeutic areas where such inhibition is beneficial.

Abstract: Compounds of the general structural formula ##STR1## and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: A compound of formula (I) and salts and solvates thereof, in which: R.sup.0 represents hydrogen, halogen, or C.sub.1-6 alkyl; R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl, or heteroarylC.sub.1-3 alkyl; R.sup.2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring (a) attached to the rest of the molecule via one of the benzene ring carbon atoms, and wherein the fused ring (A) is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen; and R.sup.3 represents hydrogen or C.sub.1-3 alkyl, or R.sup.1 and R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain.

Abstract: The use of (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-p yrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (3S 6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyhenyl) -pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and physiologically acceptable salts and solvates thereof, in methods and compositions for the treatment of impotence.

Abstract: A compound of formula (I) ##STR1## and salts and solvates thereof, in which: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl;R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cyloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl or heteroarylC.sub.1-3 alkyl;R.sup.2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring ##STR2## attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; andR.sup.3 represents hydrogen or C.sub.1-3 alkyl, or R.sup.1 and R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain.

Abstract: A compound of formula (I) ##STR1## and salts and solvates thereof, in which: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl;R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl or heteroarylC.sub.1-3 alkyl;R.sup.2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring ##STR2## attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; andR.sup.3 represents hydrogen or C.sub.1-3 alkyl, or R.sup.1 and R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain.

Abstract: A compound of formula ##STR1## and salts and solvates thereof, wherein R.sup.0, R.sup.1, and R.sup.2 are defined in the specification. A compound of the present invention is a potent and selective inhibitor of cGMP-specific PDE and has utility in a variety of therapeutic areas where such inhibition is beneficial.

Abstract: A compound having the formula (I) ##STR1## and solvates thereof, wherein: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl;R.sup.1 represents hydrogen or C.sub.1-6 alkyl;R.sup.2 represents the bicyclic ring ##STR2## which may be optionally substituted by one or more groups selected from halogen and C.sub.1-3 alkyl; andR.sup.3 represents hydrogen or C.sub.1-3 alkyl is disclosed.The compounds are potent and selective inhibitors of cGMP-specific PDE, and are useful in a variety of therapeutic areas where such inhibition is beneficial.

Abstract: A process for the preparation of compounds of formula I ##STR1## by reacting a pyrrolopyrrole of formula ##STR2## wherein X.sub.1 is a group selected from ##STR3## X.sub.2 is a group selected from ##STR4## or has the same meaning as X.sub.1, with a secondary amine of formula ##STR5## in the molar ratio 1:2, in the presence of an anhydrous dipolar aprotic solvent and of an amount 0.1 to 15 times in excess of stoichiometric proportion, based on the amine of formula III, of an anhydrous organic base, in the temperature range from 50.degree. to 230.degree. C. and under a pressure from 0 to 10 bar.The substituents R.sub.1 to R.sub.8, Y and Hal are as defined in claim 1.The compounds of formula I are especially suitable for use as photoconductive substances.

Abstract: A compound of formula (I) ##STR1## and salts and solvates thereof, in which: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl;R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl or heteroarylC.sub.1-3 alkyl; R.sup.2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring ##STR2## attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; andR.sup.3 represents hydrogen or C.sub.1-3 alkyl, or R.sup.1 and R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain.

Abstract: Compounds are described of general formula (I) ##STR1## and salts and solvates thereof, including physiologically acceptable salts and solvates thereof, in which:Z represents either Het, ##STR2## Het represents an optionally substituted bicyclic or tricyclic ring selected from acricine isoquinolin-1-yl, isoquinolin-3-yl,The novel compounds of formula (I) can sensitize multi-drug resistant cancer cells to chemotherapeutic agents and may be formulated for use in therapy, particularly to improve or increase the efficacy of an anti-tumour drug.

Abstract: Process for the manufacture of 2-(2-hydroxyphenyl)benztriazoles of the formula I ##STR1## wherein R.sub.1 denotes hydrogen or halogen, R.sub.2 denotes hydrogen, alkyl, alkoxy, alkylsulphonyl, acylamino, --SO.sub.3 H, --COOH or halogen, R.sub.3 denotes hydrogen, alkyl, cycloalkyl, aralkyl, aryl or halogen, R.sub.4 denotes hydrogen, alkyl, alkoxy or --OH and R.sub.5 denotes hydrogen, alkyl, cycloalkyl, aralkyl, aryl, carboxyalkyl, alkoxy, acylamino or halogen, characterized in that a 2-(2-hydroxyphenyl)-benztriazole-1 oxide in the formula III ##STR2## is reacted with 0.5 to 0.6 mol equivalent of hydrazine hydrate at a temperature above 100.degree. C, in a high-boiling ether as the solvent and in the presence of a base.

Abstract: Substituted 2-nitro-2'-hydroxy-azobenzenes are manufactured by coupling a phenol dispersed with a dispersing agent in water with a solution, in an inorganic acid, of a diazotized o-nitroaniline at a pH value not exceeding 2.The azobenzenes obtained are intermediate products for benztriazoles.